Thermo Fisher Scientific (TMO) Cash from Financing Activities (2009 - 2026)

Thermo Fisher Scientific has disclosed Cash from Financing Activities across 18 years of filings, most recently posting $1.1 billion for Q1 2026.

• Quarterly Cash from Financing Activities rose 1171.57% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 159.06% YoY) and the FY2025 annual result came in at $1.8 billion, up 126.52% from the prior year.
• Cash from Financing Activities eased to $1.1 billion in Q1 2026, from $3.5 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.5 billion in Q4 2025 and troughed at -$3.7 billion in Q4 2024.
• A 5-year average of -$607.6 million and a median of -$991.0 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 2406.58% — and 2023, when it jumped 1328.48%.
• Tracing TMO's Cash from Financing Activities over 5 years: stood at $2.4 billion in 2022, then tumbled by 159.72% to -$1.4 billion in 2023, then slumped by 156.72% to -$3.7 billion in 2024, then surged by 196.18% to $3.5 billion in 2025, then slumped by 69.0% to $1.1 billion in 2026.
• Business Quant data shows TMO's Cash from Financing Activities at $1.1 billion in Q1 2026, $3.5 billion in Q4 2025, and -$632.0 million in Q3 2025.